Ocon Therapeutics, a Modiin, Israel-based health company which specialised in drug delivery systems, raised $10M in funding.
The round was led by RH Capital, with participation from Features Capital, Astia Angels, and Exerte Partners.
The company intends to use the funds to further enhance its ability to provide solutions for treating prevalent uterine pathologies.
Led by Keren Leshem, CEO, OCON Therapeutics is a women’s health company dedicated to developing, manufacturing, and commercializing 3D drug delivery systems based on its patented IUB® (Intra-Uterine Ball) platform. Leveraging its validated 3D stent drug delivery frame IUB®, which has demonstrated safety and usability in over 150,000 women with its IUB Ballerine®, Ocon is set to advance its IUB SEAD® and IUB PRIMA® assets, both designed to tackle abnormal and heavy uterine bleeding, providing long-term hormonal and short-term non-hormonal options for treatment.
FinSMEs
24/06/2024